HOME >> MEDICINE >> NEWS
Italian researchers find fenretinide cuts the risk of second breast cancers in young women

A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] a drug related to vitamin A significantly cuts the risk of a second breast cancer among younger patients.

The Italian research team reporting the findings on-line (Thursday 4 May) in Annals of Oncology[2], are sufficiently convinced of the drug's protective potential to call for a trial to test its use as a preventive in pre-menopausal healthy women at high risk of the disease. They are now seeking international partners and funding for such a trial.

The women in the long-term follow-up comprised a sub-group of 1,700 60% of the patients in a 10-centre trial lead by Professor Umberto Veronesi and co-ordinated by Milan's Istituto Nazionale Tumori when he was its director. The study, which began in 1987, randomised more than 2,800 women to receive 200 mg fenretinide daily for five years or no extra treatment after surgery for early-stage breast cancer.

The new analysis, also lead by Professor Veronesi, who is now Director of the European Institute of Oncology in Milan, followed the 1,739 patients who had been recruited by the Istituto Nazionale Tumori centre, investigating whether these patients developed a second cancer either in the treated breast or the other breast.

Co-author Dr Andrea Decensi, Director of the Department of Medical Oncology at the Galliera Hospital in Genoa, said: "We followed these patients for between 12 and 16 years and we found 168 second breast cancers in the fenretinide arm and 190 in the control arm. In post-menopausal women there were actually more cancers in the fenretinide arm than among the controls (85 as against 64). But, among pre-menopausal women there were only 83 second cancers in the fenretinide group compared with 126 in the control group.

Dr Decensi said that overall, this meant a 17% reduction in second cancers among the fenretinide group, which was of borderline statistical significance. But, there we
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-015-367-72181
European Society for Medical Oncology
3-May-2006


Page: 1 2 3

Related medicine news :

1. UCLA, Italian chemists move closer to solving Lou Gehrigs disease mystery
2. Italian doctors get their information on medicines from drug company sales reps
3. Italian public smoking ban leads to fall in hospital heart attack admissions in under 60s
4. UPMC joins Italian government to create $398 million biomedical research center in Sicily
5. Italian law on ART brings problems for doctors and patients
6. Stanford researchers find culprit in aging muscles that heal poorly
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Penn researchers discover novel pathway for increasing good cholesterol
9. Theory of facial aging gets a facelift from UT Southwestern researchers
10. UIC researchers to develop new drugs to fight bioterrorism
11. UQ researchers discover some of the oldest forms of life

Post Your Comments:
(Date:7/7/2015)... , ... July 07, 2015 ... ... on highly educated and motivated leaders with strong managerial expertise to oversee ... clearly communicate with patients, staff, providers, business partners, insurance companies, and regulators. ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... an official accrediting body as designated by the Centers for Medicare and Medicaid ... experience and to enhance compatibility with mobile devices. , The most effective websites ...
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... a leading provider of unified communication management solutions, has announced the release ... Select. , This service pack includes a number of enhancements to the ...
(Date:7/7/2015)... MO (PRWEB) , ... July 07, 2015 , ... ... liability law announce the launch of their new website, the Invokana Ketoacidosis ... Invokana FDA warning*, and serves as a resource for persons wishing to learn ...
(Date:7/7/2015)... ... ... On May 29, 2015, Health Canada announced that they had registered a ... gluten free oats and foods that contain them as ingredients. , “We are very ... include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory and Technical ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4
(Date:7/6/2015)... PITTSBURGH , July 6, 2015  Student-athletes ... will benefit from a recently established partnership ... California . The partnership enables ... (S.A.I.N.) to distribute ImPACT ® concussion baseline ... insures the majority of community colleges in ...
(Date:7/6/2015)... , July 6, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in New York City.  The public is ... webcast on the Array BioPharma website. Event: Cantor Fitzgerald ... 8, 2015Time:1:00 p.m. Eastern Time Webcast: www.arraybiopharma.com About ...
(Date:7/6/2015)... July 6, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... neuroblocking technology to treat obesity, metabolic diseases, and other ... and cancellation of its previously announced underwritten public offering ... of $0.87 per unit. Canaccord Genuity ... Group was acting as co-manager for the offering. ...
Breaking Medicine Technology:California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 2California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 3EnteroMedics Inc. Announces Termination of Public Offering of Common Stock and Warrants 2
Cached News: